实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (6): 907-910.doi: 10.3969/j.issn.1672-5069.2023.06.035

• 肝癌 • 上一篇    下一篇

接受根治性肝切除术治疗的肝内胆管细胞癌患者肿瘤组织成纤维细胞生长因子受体2表达及其临床意义探讨*

孙岩, 张鑫, 李国宾, 闫尚伦, 徐良   

  1. 222000 江苏省连云港市 南京医科大学康达学院附属连云港市第二人民医院普外科
  • 收稿日期:2023-06-21 出版日期:2023-11-10 发布日期:2023-11-20
  • 通讯作者: 徐良,E-mail:lygeyxl@163.com
  • 作者简介:孙岩,男,40岁,大学本科,主治医师。E-mail:s121315996111784@126.com
  • 基金资助:
    * 江苏省科技厅社会发展面上项目 (编号:BE2020708)

Expression of fibroblast growth factor receptor 2 in cancerous tissues and its implication in patients with intrahepatic cholangiocarcinoma underwent radical hepatectomy

Sun Yan, Zhang Xin, Li Guobin, et al   

  1. Department of General Surgery, Second People's Hospital Affiliated to Kangda College, Nanjing Medical University, Lianyungang 222000, Jiangsu Province, China
  • Received:2023-06-21 Online:2023-11-10 Published:2023-11-20

摘要: 目的 探讨接受根治性肝切除术治疗的肝内胆管细胞癌(ICC)患者肿瘤组织成纤维细胞生长因子受体2表达及其与预后的关系。方法 2017年3月~2022年4月我院诊治的ICC患者56例,均接受肝叶切除术治疗,随访1年。采用免疫组化法检测肿瘤组织FGFR2表达。采用单因素和多因素Logistic回归分析影响无病生存期(DFS)的因素。结果 本组肿瘤组织FGFR2阳性15例(26.8%),阴性41例(73.2%);FGFR2阳性组发生微血管侵袭比例为66.7%,显著高于FGFR2阴性组的29.3%(P<0.05);FGFR2阳性组血清CEA水平为5.9(1.3,55.2)ng/mL,显著高于FGFR2阴性组【2.2(0.5,26.4)ng/mL,P<0.05】;术后随访1年,FGFR2阳性组1 a DFS为33.3%,显著低于FGFR2阴性组的58.5%(P<0.05);多因素分析发现,最大肿瘤直径、肿瘤部位和FGFR2阳性表达是影响患者预后的独立危险因素(P<0.05)。结论 FGFR2高表达可能是ICC患者术后肿瘤复发的危险因素,针对这类患者有必要采取更加科学的随访计划和管理措施。

关键词: 肝内胆管细胞癌, 成纤维细胞生长因子受体2, 表达, 预后

Abstract: Objective The aim of this study was to investigate the expression of fibroblast growth factor receptor 2 (FGFR2) in cancerous tissues and its implication in patients with intrahepatic cholangiocarcinoma (ICC) underwent radical hepatectomy. Methods 56 patients with ICC were encountered in our hospital between March 2017 and April 2022, and all underwent radical hepatectomy. All patients were followed-up for one year. The expression of FGFR2 in cancerous tissues was detected by immunochemical staining. The univariate and multivariate Logistic regression analysis were applied to predict the factors impacting the disease-free survival (DFS). Results The expression of FGFR2 in cancerous tissues was positive in 15 cases(26.8%) and negative in 41 cases (73.2%); the incidence of microvascular invasion in FGFR2 positive group was 66.7%, significantly higher than 29.3% in FGFR2 negative group (P<0.05); serum CEA level in FGFR2 positive group was 5.9(1.3, 55.2)ng/mL, much higher than [2.2(0.5, 26.4)ng/mL, P<0.05] in FGFR2 negative group; at the end of one-year follow-up, the DFS in FGFR2 positive group was 33.3%, much lower than 58.5%(P<0.05) in FGFR2 negative group; the multivariate Logistic regression analysis showed that the tumor diameters, the locations of tumor and the FGFR2 positive expression were the independent risk factors impacting the prognosis of patients with ICC after operation (P<0.05). Conclusion The intensified expression of FGFR2 in cancerous tissues is an independent risk factor for postoperative recurrence of tumor and poor prognosis in patients with ICC, which should be taken into consideration for close surveillance.

Key words: Intrahepatic cholangiocarcinoma, Fibroblast growth factor receptor 2, Expression, Prognosis